Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.62 |
| ▸ | PGR | P06401 | 5/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327967 | 0.91 | AR (0.57) | ARPGRNR3C1 | |
| SCHEMBL3132245 | 0.82 | AR (0.63) | ARPGRNR3C1 | |
| SCHEMBL3005707 | 0.77 | AR (1.00) | ARPGRNR3C1 | |
| SCHEMBL3019235 | 0.74 | AR (0.60) | ARPGR | |
| SCHEMBL3017276 | 0.70 | AR (0.61) | ARPGR | |
| SCHEMBL3023963 | 0.69 | AR (1.00) | ARPGRNR3C1 | |
| SCHEMBL3019330 | 0.68 | AR (0.75) | ARPGRNR3C1 | |
| SCHEMBL5521984 | 0.68 | RXFP1 (0.38) | AR | |
| SCHEMBL2864168 | 0.68 | AR (0.66) | ARPGRNR3C1 | |
| SCHEMBL3012964 | 0.67 | AR (1.00) | ARPGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212330-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2006-04-19 | — | — | EP | claimed |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC, | 2003-10-02 | — | — | US | claimed |
| US-6462038-B1 | SUCH AS 1,2,3,6-TETRAHYDRO-1-METHYL-9-(TRIFLUOROMETHYL)-7H-(1,4)OXAZINO(3,2 -G)QUINOLIN-7-ONE; NONSTEROIDAL, HIGH AFFINITY AND SPECIFICITY ANTAGONISTS AND AGONISTS OR PARTIAL AGONISTS, I.E. PARTIAL AND/OR TISSUE SPECIFIC ACTIVATORS | LIGAND PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1212330-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016139-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | claimed |
| US-20100204216-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION | SUMMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2199284-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING ACCUMULATION OF AMYLOID- BETA PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1212330-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC, | 2003-10-02 | — | — | US | disclosed |
| US-6462038-B1 | SUCH AS 1,2,3,6-TETRAHYDRO-1-METHYL-9-(TRIFLUOROMETHYL)-7H-(1,4)OXAZINO(3,2 -G)QUINOLIN-7-ONE; NONSTEROIDAL, HIGH AFFINITY AND SPECIFICITY ANTAGONISTS AND AGONISTS OR PARTIAL AGONISTS, I.E. PARTIAL AND/OR TISSUE SPECIFIC ACTIVATORS | LIGAND PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204216-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION | APP, PSEN1, IAPP | AR 3600/4885PGR 4342/4885NR3C1 2128/4885 |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885PGR 96/4885NR3C1 20/4885 |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885PGR 44/4885NR3C1 21/4885 |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885PGR 96/4885NR3C1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.